Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.

On CNBC's "Mad Money Lightning Round," Jim Cramer praised home improvement retailer Lowe's Companies and CrowdStrike Holdings ...

GSK (GSK) stock in focus as the company secures EU approval for Blenrep combo therapies targeting the blood cancer multiple ...

The Swiss drugmaker discussed the option of selling drugs directly to patients with U.S. officials following Trump ...

However, yesterday GSK announced that the FDA has extended the review period for Blenrep to give the agency time to review ...

"Longer follow-ups after the pandemic are needed to investigate persistent brain aging effects and their long-term ...

Roche is considering selling its prescription medicines in the U.S. directly to consumers to lower costs for patients as part ...

Rocket Pharmaceuticals will cut 80 jobs and streamline operations, focusing on gene therapies to drive long-term growth.

Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...

In this exclusive Drug Digest video, Deepak Bahl from Roquette and Jagruti Patel from Lonza look at strategies for ...

Dispatch, based in Philadelphia and San Francisco, is developing a platform to carr novel antigens to solid tumors.